Comparing DEEP Substrate Mapping and Activation Mapping to Reduce Ventricular Tachycardia Recurrence in Adults

What this Trial Is About

Researchers are evaluating two main techniques used for guiding ventricular tachycardia VT ablation substrate-based DEEP mapping and activation mapping. This randomized clinical trial aims to test whether activation mapping is better than DEEP mapping at reducing the return of ventricular tachycardia. The study focuses on comparing the success rates of these methods 12 months after the procedure and their ease of use during the procedure. The study involves two groups one will receive the substrate-based DEEP mapping approach, which identifies arrhythmogenic areas during normal heart rhythm using specialized catheters, while the other will receive VT activation mapping, which locates reentry circuits to target for ablation. Both groups use similar advanced mapping catheters and ablation devices. The procedure details and effectiveness are assessed during the procedure and followed up over time. Participants will undergo the ablation procedure guided by one of the two mapping methods. Researchers will evaluate outcomes including the recurrence-free survival rate of VT at 12 months and procedural feasibility during the initial procedure. Additional measurements include procedural data, tolerance to VT during the procedure, and clinical follow-up information after 12 months. The total study duration includes initial treatment and at least one year of follow-up to monitor long-term effects.

DEEP Substrate Mapping Versus Activation Mapping for VT